Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004988:Ethers, Cyclic / Q000627:therapeutic use / Q000633:toxicity; D005047:Etoposide / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D004376:Galactitol / Q000031:analogs & derivatives / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013402:Sugar Alcohols / Q000627:therapeutic use*
D004988:Ethers, Cyclic; D013402:Sugar Alcohols; D004376:Galactitol; D005047:Etoposide; D011034:Podophyllotoxin